EyeGene Inc - Asset Resilience Ratio

Latest as of March 2026: 53.36%

EyeGene Inc (185490) has an Asset Resilience Ratio of 53.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check EyeGene Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

₩34.53 Billion

≈ $23.40 Million USD Cash + Short-term Investments

Total Assets

₩64.70 Billion

≈ $43.85 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how EyeGene Inc's Asset Resilience Ratio has changed over time. See 185490 equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down EyeGene Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 185490 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩34.53 Billion	53.36%
Total Liquid Assets	₩34.53 Billion	53.36%

Asset Resilience Insights

Very High Liquidity: EyeGene Inc maintains exceptional liquid asset reserves at 53.36% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

EyeGene Inc Industry Peers by Asset Resilience Ratio

Compare EyeGene Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for EyeGene Inc (2014–2025)

The table below shows the annual Asset Resilience Ratio data for EyeGene Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	51.88%	₩35.30 Billion ≈ $23.92 Million	₩68.05 Billion ≈ $46.12 Million	+3.36pp
2024-12-31	48.52%	₩31.68 Billion ≈ $21.47 Million	₩65.31 Billion ≈ $44.26 Million	-20.07pp
2023-12-31	68.58%	₩53.56 Billion ≈ $36.30 Million	₩78.10 Billion ≈ $52.93 Million	-13.14pp
2022-12-31	81.72%	₩65.69 Billion ≈ $44.52 Million	₩80.38 Billion ≈ $54.47 Million	+1.19pp
2021-12-31	80.54%	₩84.56 Billion ≈ $57.30 Million	₩104.99 Billion ≈ $71.15 Million	+6.18pp
2020-12-31	74.36%	₩33.04 Billion ≈ $22.39 Million	₩44.43 Billion ≈ $30.11 Million	-4.20pp
2019-12-31	78.56%	₩37.17 Billion ≈ $25.19 Million	₩47.31 Billion ≈ $32.06 Million	-7.96pp
2018-12-31	86.52%	₩46.76 Billion ≈ $31.69 Million	₩54.04 Billion ≈ $36.62 Million	+10.89pp
2017-12-31	75.63%	₩22.90 Billion ≈ $15.52 Million	₩30.28 Billion ≈ $20.52 Million	+9.68pp
2016-12-31	65.95%	₩12.24 Billion ≈ $8.29 Million	₩18.56 Billion ≈ $12.58 Million	-5.66pp
2015-12-31	71.61%	₩17.42 Billion ≈ $11.81 Million	₩24.33 Billion ≈ $16.49 Million	+35.39pp
2014-12-31	36.23%	₩2.01 Billion ≈ $1.36 Million	₩5.54 Billion ≈ $3.76 Million	--

pp = percentage points

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$29.03 Million

₩42.83 Billion KRW

Market Cap Rank

#23926 Global

#1646 in Korea

Share Price

₩1406.00

Change (1 day)

+0.07%

52-Week Range

₩1193.00 - ₩3630.00

All Time High

₩50300.00